JP2025507915A - ジアシルグリセロールキナーゼ(DGK)α阻害剤及びその使用 - Google Patents

ジアシルグリセロールキナーゼ(DGK)α阻害剤及びその使用 Download PDF

Info

Publication number
JP2025507915A
JP2025507915A JP2024552219A JP2024552219A JP2025507915A JP 2025507915 A JP2025507915 A JP 2025507915A JP 2024552219 A JP2024552219 A JP 2024552219A JP 2024552219 A JP2024552219 A JP 2024552219A JP 2025507915 A JP2025507915 A JP 2025507915A
Authority
JP
Japan
Prior art keywords
heterocycloalkyl
cycloalkyl
alkyl
heteroaryl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024552219A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025507915A5 (cg-RX-API-DMAC7.html
Inventor
ホンフー ルー
ホアシン ユイ
シアオ ティン
フォン レン
Original Assignee
インシリコ メディスン アイピー リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by インシリコ メディスン アイピー リミティド filed Critical インシリコ メディスン アイピー リミティド
Publication of JP2025507915A publication Critical patent/JP2025507915A/ja
Publication of JP2025507915A5 publication Critical patent/JP2025507915A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024552219A 2022-03-01 2023-03-01 ジアシルグリセロールキナーゼ(DGK)α阻害剤及びその使用 Pending JP2025507915A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
CN2022078655 2022-03-01
CNPCT/CN2022/078655 2022-03-01
CNPCT/CN2022/091215 2022-05-06
CN2022091215 2022-05-06
CN2022128282 2022-10-28
CNPCT/CN2022/128282 2022-10-28
CN2023071962 2023-01-12
CNPCT/CN2023/071962 2023-01-12
PCT/CN2023/078973 WO2023165509A1 (en) 2022-03-01 2023-03-01 Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof

Publications (2)

Publication Number Publication Date
JP2025507915A true JP2025507915A (ja) 2025-03-21
JP2025507915A5 JP2025507915A5 (cg-RX-API-DMAC7.html) 2026-03-09

Family

ID=87883015

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024552219A Pending JP2025507915A (ja) 2022-03-01 2023-03-01 ジアシルグリセロールキナーゼ(DGK)α阻害剤及びその使用

Country Status (7)

Country Link
US (1) US20250214990A1 (cg-RX-API-DMAC7.html)
EP (1) EP4486745A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025507915A (cg-RX-API-DMAC7.html)
CN (1) CN118829642A (cg-RX-API-DMAC7.html)
AR (1) AR128668A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342478A (cg-RX-API-DMAC7.html)
WO (1) WO2023165509A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315015A (en) 2022-03-01 2024-10-01 Insilico Medicine Ip Ltd Diacylglycerol kinase (DGK) alpha inhibitors and their uses
TW202436351A (zh) 2023-02-06 2024-09-16 德商拜耳廠股份有限公司 Ccr8抗體及dgk抑制劑之組合
CN122094689A (zh) * 2023-09-04 2026-05-26 英矽智能科技知识产权有限公司 二酰甘油激酶(DGK)α抑制剂与其他疗法的组合治疗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075747A1 (en) * 2009-12-18 2011-06-23 Glaxosmithkline Llc Therapeutic compounds
CN112654621B (zh) * 2018-06-27 2024-05-14 百时美施贵宝公司 可作为t细胞活化剂的经取代萘啶酮化合物
WO2021105115A1 (en) * 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
IL294148A (en) * 2019-12-23 2022-08-01 Bristol Myers Squibb Co Substituted quinazolinyl compounds are useful as t-cell activators
CN115362003B (zh) * 2019-12-24 2024-03-22 卡尔那生物科学株式会社 二酰基甘油激酶调节化合物
MX2023014762A (es) * 2021-06-23 2024-01-15 Gilead Sciences Inc Compuestos moduladores de diacilglicerol quinasa.

Also Published As

Publication number Publication date
CN118829642A (zh) 2024-10-22
EP4486745A4 (en) 2026-03-11
EP4486745A1 (en) 2025-01-08
US20250214990A1 (en) 2025-07-03
AR128668A1 (es) 2024-06-05
TW202342478A (zh) 2023-11-01
WO2023165509A1 (en) 2023-09-07

Similar Documents

Publication Publication Date Title
EP4480953B1 (en) Tyk2 inhibitors and uses thereof
JP7802106B2 (ja) ピラゾリル-アミノ-ピリミジニル誘導体のベンズアミド、およびその組成物ならびに方法
CA3069829A1 (en) Aryl-phosphorus-oxygen compound as egfr kinase inhibitor
JP2026508072A (ja) Kif18aの阻害薬およびその使用
CA3134261A1 (en) 6-(isooxazolidin-2-yl)-n-phenylpyrimidin-4-amine derivatives as inhibitors of epidermal growth factor receptors
AU2014228574B2 (en) SHIP1 modulators and methods related thereto
JP2025508971A (ja) ジアシルグリセロールキナーゼ(DGK)α阻害剤及びその使用
TW202521544A (zh) TNFα活性調節劑及其用途
WO2023066283A1 (en) Methionine adenosyltransferase 2a (mat2a) inhibitors and uses thereof
WO2023165525A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
JP2024541910A (ja) プロリルヒドロキシラーゼドメイン含有タンパク質(phd)阻害剤およびその使用方法
US20250214990A1 (en) Diacylglycerol kinase (dgk) alpha inhibitors and uses thereof
EP4206197A1 (en) Preparation method for novel rho-related protein kinase inhibitor and intermediate in preparation method
TW202412760A (zh) Cbl-b抑制劑及其使用方法
WO2024141015A1 (en) Protein tyrosine phosphatase inhibitors and uses thereof
EA052540B1 (ru) Ингибиторы альфа-диацилглицеринкиназы (дгк) и способы их применения
TW202440093A (zh) Cdk8/19雙重抑制劑及其使用方法
WO2025261355A1 (en) Werner syndrome recq helicase (wrn) inhibitors and methods of uses thereof
WO2026024795A1 (en) F-atp hydrolase inhibitors
CN120712269A (zh) Fgfr2和fgfr3的抑制剂及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260227